<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">ketendo</journal-id><journal-title-group><journal-title xml:lang="ru">Клиническая и экспериментальная тиреоидология</journal-title><trans-title-group xml:lang="en"><trans-title>Clinical and experimental thyroidology</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1995-5472</issn><issn pub-type="epub">2310-3787</issn><publisher><publisher-name>Endocrinology Research Centre</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.14341/ket20106354-59</article-id><article-id custom-type="elpub" pub-id-type="custom">ketendo-4284</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>Статьи</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>Articles</subject></subj-group></article-categories><title-group><article-title>Оценка динамики показателей липидного спектра и ранних предикторов эндотелиальной дисфункции при первичном гипотиреозе в зависимости от уровня ТТГ в пределах референсного диапазона</article-title><trans-title-group xml:lang="en"><trans-title>Lipid profile and early predictors of endothelian dysfunction in hypothyroidism against the TSH level within reference range</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Podzolkov</surname><given-names>A V</given-names></name></name-alternatives><email xlink:type="simple">-</email></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Fadeyev</surname><given-names>V V</given-names></name></name-alternatives><email xlink:type="simple">walfad@mail.ru</email></contrib></contrib-group><pub-date pub-type="collection"><year>2010</year></pub-date><pub-date pub-type="epub"><day>15</day><month>09</month><year>2010</year></pub-date><volume>6</volume><issue>3</issue><issue-title>ТОМ 6, №3 (2010)</issue-title><fpage>54</fpage><lpage>59</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Podzolkov A.V., Fadeyev V.V., 2010</copyright-statement><copyright-year>2010</copyright-year><copyright-holder xml:lang="ru">Podzolkov A.V., Fadeyev V.V.</copyright-holder><copyright-holder xml:lang="en">Podzolkov A.V., Fadeyev V.V.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.cet-endojournals.ru/jour/article/view/4284">https://www.cet-endojournals.ru/jour/article/view/4284</self-uri><abstract><p>Гипотиреоз является заболеванием, способствующим развитию атеросклероза и сердечно-сосудистых осложнений. Повышенный уровень общего холестерина, липопротеидов низкой плотности, триглицеридов, С-реактивного белка и гомоцистеина расценивается как дополнительный фактор риска развития сердечно-сосудистых заболеваний и эндотелиальной дисфункции. Было обследовано 60 женщин с диагнозом “первичный гипотиреоз”, находящихся на заместительной терапии левотироксином. Пациентки были разделены на 2 группы по 30 человек в зависимости от исходного уровня ТТГ. В 1-ю группу вошли женщины с низконормальными показателями ТТГ в пределах (0,4–2,0 мЕд/л), во 2-ю – с высоконормальным ТТГ (2,1–4,0 мЕд/л). Оценивались показатели липидного спектра и ранних предикторов эндотелиальной дисфункции на начальном этапе исследования и через 3 мес после модификации дозы принимаемого LT4. На старте исследования было выявлено, что женщины из группы с высоконормальным ТТГ имеют достоверно более высокие значения общего холестерина ( p = 0,002 ), липопротеидов низкой плотности ( р = 0,02 ), ТГ ( р = 0,03 ). После уменьшения дозы принимаемого левотироксина в этой группе с переходом ее в высоконормальный интервал значений ТТГ было отмечено достоверное увеличение атерогенной фракции липопротеидов низкой плотности ( р = 0,02 ). После увеличения во 2-й группе дозы L-T4 и перехода из высоконормального диапазона ТТГ в низконормальный было отмечено достоверное снижение уровня ранних предикторов эндотелиальной дисфункции – С-реактивного белка (0,004) и гомоцистеина (0,05). Существенной динамики показателей липидного спектра выявлено не было. Таким образом, можно сделать вывод, что модификация заместительной терапии гипотиреоза, обеспечивающая поддержание низконормального уровня ТТГ (0,4–2,0 мЕд/л) приводит к достоверному снижению уровня предикторов эндотелиальной дисфункции (Среактивного белка и гомоцистеина).</p></abstract><trans-abstract xml:lang="en"><p>Hypothyroidism is associated with premature atherosclerosis and cardiovascular disease. High levels of total cholesterol, low-density lipoprotein cholesterol (LDL-C), triglycerides and recently, homocysteine (Hcy) and C-reactive protein (CRP) emerged as additional cardiovascular risk factors. Sixty ambulatory patients with primary hypothyroidism receiving levothyroxine (L-T4) participated in the study. Patients were divided into 2 groups according to their TSH level. The first group was in TSH low-normal range (0.4–2.0 mU/l), the second in upper-normal (2.1–4.0 mU/l) range. We analyzed the results of lipid profile data, CRP and HCY levels at baseline and in 3 months. With a small-dose changes we cross the groups to compare the results. Patients in upper-normal range group had significantly higher levels of total cholesterol (p = 0.002), LDL-C (p = 0.02), triglycerides (p = 0.03) at baseline. After decreasing the dose of L-T4 in group with low-normal TSH range there were no significant difference in levels of total cholesterol and triglycerides. After dose-changing the level of LDL-C was significantly higher in group with upper-normal TSH range (p = 0.02). After increasing the L-T4 dose in group with upper-normal TSH range we didn't find any significant differences in lipid profile level, but the early predictors of endothelium dysfunction were sig-nificantly lower in group with low-normal TSH range: CRP (p = 0.004), HCY (p =0.05). Conclusion: Small-changes in L-T4 dose which help to achieve the low-normal TSH range leads to significantdecrease in levels of early predictors of en-dothelium dysfunction – C-reactive protein and homocysteine.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>ТТГ</kwd><kwd>С-реактивный белок</kwd><kwd>гомоцистеин</kwd><kwd>липидный профиль</kwd><kwd>низконормальный диапазон ТТГ</kwd><kwd>высоконормальный диапазон ТТГ</kwd></kwd-group><kwd-group xml:lang="en"><kwd>TSH</kwd><kwd>C-reactive protein</kwd><kwd>Homocysteine</kwd><kwd>Lipid Profile</kwd><kwd>Low-normal TSH range</kwd><kwd>Uppernormal TSH range</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis // JAMA. 2002. V. 288. N16. P. 2015–2022.</mixed-citation><mixed-citation xml:lang="en">Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis // JAMA. 2002. V. 288. N16. P. 2015–2022.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Baloch Z., Carayon P., Conte-Devolx B. et al. Laboratory medicine practice guidelines. Laboratory support for the diagnosis and moitoring of thyroid disease // Thyroid. 2003. V. 13. N1. P. 3–126.</mixed-citation><mixed-citation xml:lang="en">Baloch Z., Carayon P., Conte-Devolx B. et al. Laboratory medicine practice guidelines. Laboratory support for the diagnosis and moitoring of thyroid disease // Thyroid. 2003. V. 13. N1. P. 3–126.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Gursoy A., Ozduman Cin M., Kamel N., Gullu S. Which thyroidstimulating hormone level should be sought in hypothyroid patients under L-thyroxine replacement therapy? // Intern. J. Cin. Pract. 2006. V. 60. N6. P. 655–659.</mixed-citation><mixed-citation xml:lang="en">Gursoy A., Ozduman Cin M., Kamel N., Gullu S. Which thyroidstimulating hormone level should be sought in hypothyroid patients under L-thyroxine replacement therapy? // Intern. J. Cin. Pract. 2006. V. 60. N6. P. 655–659.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Hollowell J.G., Staehling N.W., Flanders W.D. et al. Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III) // J. Clin. Endocrinol. Metab. 2002. V. 87. N2. P. 489–499.</mixed-citation><mixed-citation xml:lang="en">Hollowell J.G., Staehling N.W., Flanders W.D. et al. Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III) // J. Clin. Endocrinol. Metab. 2002. V. 87. N2. P. 489–499.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Lopez-Quesada E., Vilaseca M.A., Lailla J.M. Plasma total homocysteine in uncomplicated pregnancy and in preeclampsia // Eur. J. Obstet. Gynecol. Reproduct. Biol. 2003. V. 108. N1. P. 45–49.</mixed-citation><mixed-citation xml:lang="en">Lopez-Quesada E., Vilaseca M.A., Lailla J.M. Plasma total homocysteine in uncomplicated pregnancy and in preeclampsia // Eur. J. Obstet. Gynecol. Reproduct. Biol. 2003. V. 108. N1. P. 45–49.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Powers R.W., Evans R.W., Majors A.K. et al. Plasma homocysteine concentration is increased in preeclampsia and is associated with evidence of endothelial activation // Am. J. Obstet. Gynecol. 1998. V. 179. N6. P. 1605–1611.</mixed-citation><mixed-citation xml:lang="en">Powers R.W., Evans R.W., Majors A.K. et al. Plasma homocysteine concentration is increased in preeclampsia and is associated with evidence of endothelial activation // Am. J. Obstet. Gynecol. 1998. V. 179. N6. P. 1605–1611.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Selhub J., Jacques P.F., Bostom A.G. et al. Relationship between plasma homocysteine, vitamin status and extracranial carotidartery stenosis in the Framingham Study population // J. Nutrit. 1996. V. 126. N4. P. 1258S–1265S.</mixed-citation><mixed-citation xml:lang="en">Selhub J., Jacques P.F., Bostom A.G. et al. Relationship between plasma homocysteine, vitamin status and extracranial carotidartery stenosis in the Framingham Study population // J. Nutrit. 1996. V. 126. N4. P. 1258S–1265S.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Selhub J., Jacques P.F., Bostom A.G. et al. Relationship between plasma homocysteine and vitamin status in the Framingham study population. Impact of folic acid fortification // Publ. Healt. Rev. 2000. V. 28. N1–4. P. 117–145.</mixed-citation><mixed-citation xml:lang="en">Selhub J., Jacques P.F., Bostom A.G. et al. Relationship between plasma homocysteine and vitamin status in the Framingham study population. Impact of folic acid fortification // Publ. Healt. Rev. 2000. V. 28. N1–4. P. 117–145.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Teixeira Pde F., Reuters V.S., Ferreira M.M. Lipid profile in different degrees of hypothyroidism and effects of levothyroxine replacement in mild thyroid failure // Transl. Res 2008. V. 151. N4. P. 224–231.</mixed-citation><mixed-citation xml:lang="en">Teixeira Pde F., Reuters V.S., Ferreira M.M. Lipid profile in different degrees of hypothyroidism and effects of levothyroxine replacement in mild thyroid failure // Transl. Res 2008. V. 151. N4. P. 224–231.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Volzke H., Alte D., Kohlmann T. et al. Reference intervals of serum thyroid function tests in a previously iodine-deficient area // Thyroid 2005. V. 15. N3. P. 279–285.</mixed-citation><mixed-citation xml:lang="en">Volzke H., Alte D., Kohlmann T. et al. Reference intervals of serum thyroid function tests in a previously iodine-deficient area // Thyroid 2005. V. 15. N3. P. 279–285.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Volzke H., Robinson D.M., Spielhagen T. et al. Are serum thyrotropin levels within the reference range associated with endothelial function? // Eur. Heart. J. 2009. V. 30. N2. P. 217–224.</mixed-citation><mixed-citation xml:lang="en">Volzke H., Robinson D.M., Spielhagen T. et al. Are serum thyrotropin levels within the reference range associated with endothelial function? // Eur. Heart. J. 2009. V. 30. N2. P. 217–224.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
